- API
Vaccine Hesitancy for COVID-19: Public Use Microdata Areas (PUMAs)
data.cdc.gov | Last Updated 2021-06-17T19:56:28.000ZDue to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31. County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw
- API
Cumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years
data.cdc.gov | Last Updated 2024-05-03T13:59:26.000ZCumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years • These monthly flu vaccination coverage estimates for pregnant persons are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC’s Immunization Safety Office and nine integrated health care organizations.§ This system has been used annually to estimate vaccination coverage among pregnant persons. COVID-19 vaccination coverage for pregnant persons is available here. • Figure 3A. Monthly Cumulative Influenza Vaccination Coverage*, by Flu Season and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • Figure 3B. Cumulative Influenza Vaccination Coverage*, by Month, Flu Season, and Race/Ethnicity, Pregnant Persons 18-49 years, United States, Data Source: Vaccine Safety Datalink • For any month’s coverage estimate, the denominator is the number of persons with a pregnancy during the current flu season (defined as August through March) beginning before or during the specified month. The numerator is the subset of the denominator who have received flu vaccination prior to, during, or after pregnancy. The denominator increases as more persons are identified as pregnant or having been pregnant during the flu season. Cumulative vaccination coverage for one month may be lower than cumulative coverage for a previous month due to addition to the denominator of persons who are less likely to have received vaccination.
- API
NNDSS - Table I. infrequently reported notifiable diseases
data.cdc.gov | Last Updated 2017-01-05T16:46:43.000ZNNDSS - Table I. infrequently reported notifiable diseases - 2016. In this Table, provisional* cases of selected† infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. “Symbols and footnotes changed in week #4, please refer to the MMWR publication for the symbols/footnotes for weeks 1, 2, and 3”. Footnote: -: No reported cases N: Not reportable NA: Not available NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Case counts for reporting year 2016 are provisional and subject to change. Data for years 2011 through 2015 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. † This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. § Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Not reportable in all reporting jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. †† Office of Management and Budget approval of the NNDSS Revision #0920-0728 on January 21, 2016, authorized CDC to receive data for these conditions. CDC is in the process of soliciting data for these conditions (except Zika virus, congenital infection). CDC and the U.S. states are still modifying the technical infrastructure needed to collect and transmit data for Zika virus congenital infections. §§ Jamestown Canyon virus and Lacrosse virus have replaced California serogroup diseases. ¶¶ Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§ Data for meningococcal disease (all serogroups) are available in Table II. ¶¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition. **** Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. †††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§§ All cases reported have occurred in travelers returning from affected areas, with their sexual contacts, or infants infected in ute
- API
NNDSS - Table I. infrequently reported notifiable diseases
data.cdc.gov | Last Updated 2016-01-07T15:15:03.000ZNNDSS - Table I. infrequently reported notifiable diseases - 2015. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. �� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Data for the Arboviral disease, Chikungunya, and Hantavirus infection disease, non-Hantavirus Pulmonary Syndrome (HPS), will be displayed in this table after the CDC obtains Office of Management and Budget Paperwork Reduction Act approval to receive data for these conditions. ** Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ��ʉ�� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. ���� Data for H. influenzae (all ages, all serotypes) are available in Table II. ���� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Data for meningococcal disease (all serogroups) are available in Table II. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. **** Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.
- API
NNDSS - Table II. Giardiasis to Haemophilus influenza
data.cdc.gov | Last Updated 2016-03-03T19:42:32.000ZNNDSS - Table II. Giardiasis to Haemophilus influenza - 2014. In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (≥ 1,000 and ≤ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Data for H. influenzae (age <5 yrs serotype b, nonserotype b, and unknown serotype) are available in Table I. More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
- API
Percentage of Drivers and Front Seat Passengers Wearing Seat Belts, 2012 & 2014, Region 1 - Boston
data.cdc.gov | Last Updated 2016-09-14T12:58:06.000ZSource for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014. Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories
- API
Percentage of Drivers and Front Seat Passengers Wearing Seat Belts, 2012 & 2014, Region 1 - Boston, Column Chart
data.cdc.gov | Last Updated 2016-10-18T14:13:20.000ZSource for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014. Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories
- API
HHS Provider Relief Fund
data.cdc.gov | Last Updated 2024-07-22T03:06:18.000ZHHS is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security (CARES) Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act, which provide a total of $178 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund (PRF) money and these payments do not need to be repaid. The Department allocated $50 billion in PRF payments for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. HHS has made other PRF distributions to a wide array of health care providers and more information on those distributions can be found here: https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html
- API
CDC.gov metrics hits by year
data.cdc.gov | Last Updated 2022-07-13T17:09:55.000ZFor more information on CDC.gov metrics please see http://www.cdc.gov/metrics/
- API
Provider Relief Fund by State
data.cdc.gov | Last Updated 2024-07-22T03:06:18.000ZHHS is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security (CARES) Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act, which provide a total of $178 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund (PRF) money and these payments do not need to be repaid. The Department allocated $50 billion in PRF payments for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. HHS has made other PRF distributions to a wide array of health care providers and more information on those distributions can be found here: <a href="https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html" target="_blank" rel="nofollow external">https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html</a>